Patient Focus

Every patient has a story, a family, a future.

Our work begins — and ends — with the people we serve. We listen deeply, learn from lived experiences, and design treatments that honor each individual’s journey.

• Information for patients
• Support resources
• What to expect
• Safety and side-effect guidance
• Conversations to have with your care team

Clinical Trials Overview

Advancing treatment through compassion and evidence.

Our clinical trials are thoughtfully designed to evaluate safety, effectiveness, and real-world impact.

• Information for patients
• Current clinical trials
• Eligibility and how to join
• Trial process explained (simple steps)
• Key findings and published data
• Commitment to transparency and patient safety

BriaCell’s Patented Immunotherapy

Bria-IMT™ (for MBC)

Bria-IMT™ BriaCell is a Phase 3 lead candidate. is a patented, off-the-shelf, cell-based, targeted immunotherapy that activates the patient’s immune system to specifically kill cancer cells without harming other cells.

Upon achieving impressive survival and clinical benefit results in a Phase 2 study, BriaCell is conducting a pivotal Phase 3 study in metastatic breast cancer, which, if successful, could lead to full approval of Bria-IMT™ in combination with an immune checkpoint inhibitor.

Clinical data includes unprecedented activity in heavily pre-treated MBC patients who have failed antibody-drug conjugate therapy and in patients with metastases to the central nervous system.

BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW; TSX: BCT) is a clinical stage immuno-oncology company that is developing an entirely new class of targeted cellular immunotherapies to transform cancer care

• Lead drug candidate Bria-IMT™
• Pivotal Phase 3 study underway in advanced metastatic breast cancer (over 40K US deaths/year)
• Awarded Fast Track designation by FDA
• Single agent and combination check point inhibitor (+ CPI) activity
• Up to 2-fold increase in survival compared to comparable patients in the literature
• Unprecedented survival and clinical benefit even in CPI and antibody-drug conjugate (ADC) resistant patients
• Remarkable clinical efficacy data in patients with CNS metastases
• Bria-OTS™ & Bria-OTS+™: Next generation novel cell-based cancer immunotherapy platform
• Off-the-shelf and personalized
• Phase 1/2 bucket trial in breast cancer open with planned extension to prostate cancer, melanoma and lung cancer
• Next generation product candidate for prostate cancer (Bria-PROS+) scheduled to enter clinic in 1H2025
• National Cancer Institute Small Business Innovative Research (SBIR) award
• Experienced Management Team and Board of Directors; Clinical Strategy Team involved in 19 drug approvals.

Off-The-Shelf Personalized Immunotherapy

Bria-OTS™/Bria-OTS+™ (for MBC, prostate cancer, and other cancers)

BriaCell’s next-generation personalized off-the-shelf immunotherapy, Bria-OTS™/Bria-OTS+™, awarded numerous US and international patents and supported by clinical data of its phase 3 lead program, Bria-IMT™, forms the basis of BriaCell’s “OTS” strategy. BriaCell recently initiated patient enrollment in its Phase 1/2 bucket trial in breast/prostate/lung cancer and melanoma.

• Bria-IMT™ monotherapy is most effective in HLA-type-matched patients
• Bria-OTS™ is engineered to express 15 unique HLA types in 4 independent cell lines
• Provides matched treatment to greater than 99% of patients
• A simple saliva test provides HLA-matched personalized off-the-shelf Bria-OTS™ immunotherapy
• HLA-matched off-the-shelf therapy is faster and less costly than other expensive and complex personalized immunotherapies
• BriaCell received a Small Business Innovation Research (SBIR) award from the National Cancer Institute
• Ongoing collaboration with the NCI
• The Bria-BRES™ Phase 1/2 study is open in breast cancer.
• Bucket trial with additional cancer indications planned
• The enhanced version (Bria-OTS+™) scheduled to enter the clinic 1H2025, starting with prostate cancer